What does Tango Therapeutics do?
Tango Therapeutics, Inc. is a Nasdaq-listed clinical-stage biotechnology company developing precision oncology medicines for genetically defined cancers. It uses functional genomics, biomarker-guided patient selection, and medicinal chemistry to exploit synthetic lethality: when a tumor loses one protective pathway, blocking a second dependency may kill cancer cells while sparing normal tissue.
Which disease areas and programs define the company?
The lead asset is vopimetostat, an MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. It is being studied as monotherapy and in combinations with RAS(ON) inhibitors. TNG456 is a brain-penetrant PRMT5 inhibitor focused on MTAP-deleted glioblastoma. TNG260 is a CoREST inhibitor combined with pembrolizumab in STK11-mutant, KRAS-wild-type non-small cell lung cancer. TNG961 is an IND-enabling molecular glue intended to degrade HBS1L in FOCAD-deleted and MTAP-deleted tumors. The 2025 Form 10-K provides the complete business and pipeline context.
How does Tango Therapeutics make money?
Tango’s economic model has two stages. During development, equity financing and collaboration payments fund research, trials, and manufacturing. If a drug is approved, Tango could earn product sales directly or through a partner, plus milestones and royalties. That commercial base does not yet exist: collaboration revenue was zero in Q1 2026 after Gilead research activities concluded.
Which pipeline assets absorb the most investment?
| Economic source | Current status | Revenue quality | Key dependency |
|---|---|---|---|
| Collaboration revenue | $0 in Q1 2026; $62.4M in FY2025 | Episodic accounting recognition | Contract terms, research activity, and deferred-revenue treatment |
| Milestones and royalties | Potential future payments remain under licensed Gilead programs | Contingent and uncertain | Partner development success and commercial sales |
| Wholly owned product sales | None as of Q1 2026 | Potentially recurring after approval | Positive pivotal trials, regulatory approval, manufacturing, reimbursement, and launch execution |
| Equity financing | Major source of liquidity | Not revenue; dilutes ownership | Capital-market access and investor confidence in clinical data |
What did Tango Therapeutics’ latest financial period show?
The latest financial statements cover the quarter ended March 31, 2026. Tango reported no collaboration revenue, $48.8 million of operating expenses, and a $45.5 million net loss. Because there are no approved products, the key question is not quarterly sales momentum but whether cash burn is producing stronger clinical evidence before another financing is needed.
How did the quarter compare with Q1 2025?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Collaboration revenue | $0.0M | $5.4M | Deferred Gilead research revenue had been fully recognized by year-end 2025. |
| R&D expense | $33.5M | $36.4M | Lower discontinued-program and discovery spending offset higher vopimetostat and TNG456 investment. |
| G&A expense | $15.2M | $11.5M | Personnel-related costs, including share-based compensation, increased. |
| Net loss | $45.5M | $39.9M | Higher total operating costs and zero collaboration revenue widened the loss. |
| Net cash used in operations | $44.4M | $41.7M | Quarterly operating burn increased by $2.7 million. |
| Weighted-average shares | 143.6M | 110.3M | Equity financing reduced loss per share but expanded the ownership base. |
The Q1 2026 Form 10-Q also reported $435.8 million of total assets, $44.3 million of total liabilities, and $391.5 million of stockholders’ equity at March 31, 2026. The company had 144.2 million common shares outstanding at that date.
Vopimetostat’s combination data now dominate the investment case
On June 8, 2026, Tango reported initial Phase 1/2 data for vopimetostat with Revolution Medicines’ RAS(ON) inhibitors. Among 12 response-evaluable pancreatic-cancer patients in the daraxonrasib arm, 11 responded, producing a 92% objective response rate; nine responses were confirmed. Six-month progression-free survival was 90% and disease control was 100%. The cohort is small, heavily pretreated, and non-randomized.
What does safety and trial design imply?
Most treatment-related adverse events were Grade 1 or 2. The daraxonrasib arm had three dose-limiting toxicities in two patients at the higher dose, but no related Grade 4 or 5 events and no adverse-event discontinuations. The zoldonrasib arm had no dose-limiting toxicities or related Grade 4 or 5 events. Tango plans to finalize a front-line pancreatic-cancer Phase 3 design in 2H 2026, subject to regulatory feedback.
Which strategic turning points shaped Tango Therapeutics?
Tango’s history is best understood as a sequence of scientific narrowing and capital reallocation. The company began with a broad synthetic-lethality platform, then increasingly concentrated resources around PRMT5 biology and vopimetostat as clinical evidence accumulated.
-
2017Third Rock Ventures launched Tango with a $55 million Series A. The original thesis was to drug context-dependent cancer vulnerabilities discovered through functional genomics.
-
2020An expanded Gilead collaboration added upfront capital and validated the platform’s partnering potential, while leaving Tango responsible for its own lead assets.
-
2021The business combination with BCTG brought Tango to Nasdaq, creating a public-equity funding mechanism for clinical development.
-
2023The first vopimetostat patient was dosed in July, shifting the company’s lead value driver from preclinical promise to human clinical evidence.
-
2024Tango stopped enrollment in TNG908 after insufficient brain exposure for glioblastoma activity, demonstrating both the attrition risk and the need for a next-generation brain-penetrant molecule.
-
2025TNG456 entered the clinic, vopimetostat/RAS combination dosing began, and October monotherapy data showed 7.2-month median PFS in 29 second-line pancreatic-cancer patients and 49% ORR in a 37-patient histology-selective cohort.
-
January 2026Malte Peters became CEO, adding late-stage oncology-development experience as the company prepared for pivotal planning.
-
June 2026Positive PRMT5/RAS combination data were followed by a $600 million upsized public offering, extending management’s stated runway into 2030 and changing the company from a near-term financing story into an execution story.
The company’s official scientific approach explains how CRISPR functional genomics and biomarker selection support this strategy.
What gives Tango Therapeutics a competitive advantage?
Tango does not yet have a commercial moat. Its potential advantage combines target discovery, medicinal chemistry, biomarker-defined trials, clinical data, combination relationships, and intellectual property. The core differentiator is tolerability: vopimetostat and TNG456 are designed to cooperate with MTA that accumulates in MTAP-deleted tumors, seeking deeper tumor inhibition with less damage to normal cells.
How durable are the scientific and patent barriers?
At year-end 2025, Tango owned 11 patent families covering vopimetostat, TNG456, TNG908, and related PRMT5 inhibitors, with expected expirations extending from 2041 through 2045 before adjustments. It also disclosed five additional PRMT5 families, four CoREST families, and six HBS1L-degrader families. Their value depends on issuance, enforceability, commercial coverage, and remaining life after development.
Who are Tango Therapeutics’ main competitors?
Competition is target-specific. Tango’s 2025 filing identified BMS, Amgen, AstraZeneca, BeOne, and Abbisko as clinical-stage MTA-cooperative PRMT5 competitors. Gilead and IDEAYA were cited as additional entrants, while IDEAYA, BeOne, Insilico Medicine, and Servier were developing MAT2A inhibitors that attack the same MTAP-deletion pathway indirectly.
What market position is Tango trying to establish?
Tango is positioning vopimetostat as a preferred PRMT5 backbone for RAS-targeted combinations. Supply collaborations with Revolution Medicines, Erasca, and Lilly let Tango test complementary drugs without owning them. This broadens development options but adds dependence on partner supply, coordination, intellectual-property boundaries, and external-molecule performance.
How financially strong is Tango Therapeutics?
Tango’s liquidity improved materially after Q1 2026. Cash, equivalents, and marketable securities were $379.8 million at March 31. In June, Tango priced 18.17 million common shares and pre-funded warrants for 1.83 million shares at about $30 each, estimating $566.5 million of net proceeds. Management said combined resources should fund operations and capital needs into 2030.
What does the annual baseline reveal about burn and capital allocation?
FY2025 collaboration revenue was $62.4 million, R&D expense was $132.2 million, G&A expense was $41.5 million, net loss was $101.6 million, and operating cash use was $138.9 million. Vopimetostat direct expense rose to $26.5 million from $16.2 million in FY2024, while TNG908 and discovery spending declined. The mix shows capital shifting toward programs with stronger evidence.
The June 2026 financing filing is important because it changes discount-rate and dilution analysis. Liquidity risk falls, while the share count and future per-share economics become more diluted.
Who owns Tango Therapeutics stock, and why does governance matter?
Tango has one common-stock class with one vote per share. The April 1, 2026 proxy showed TCG Crossover II at 9.4%, Adage Capital at 7.4%, Woodline Partners at 7.0%, and BlackRock-affiliated entities at 5.9%. These stakes predated the June offering and imply dispersed institutional influence rather than founder control.
| Holder or group | Shares | Stake at April 1, 2026 | Governance implication |
|---|---|---|---|
| TCG Crossover II | 13.52M | 9.4% | Largest disclosed holder; meaningful influence without unilateral control. |
| Adage Capital Management | 10.61M | 7.4% | Specialist institutional ownership can increase scrutiny of clinical catalysts and financing decisions. |
| Woodline Partners | 10.07M | 7.0% | Another concentrated institutional block in a dispersed one-share-one-vote structure. |
| BlackRock-affiliated entities | 8.48M | 5.9% | Passive and institutional voting policies matter at annual meetings. |
| Executive officers and directors as a group | 9.35M | 6.5% | Insider incentives are meaningful but do not create voting control. |
How should investors interpret leadership and incentives?
Malte Peters became president and CEO in January 2026, replacing founding-era CEO Barbara Weber, who remained a significant holder in the proxy with 5.95 million shares, or 4.1%. The board is classified, with directors divided into staggered classes, which can slow a rapid change in control. The company’s 2026 proxy statement shows that equity compensation is a central retention tool. At March 31, 2026, Tango also had $77.1 million of unrecognized stock-option compensation and $16.5 million of unrecognized restricted-stock-unit compensation, creating future expense and dilution considerations.
What opportunities and risks could change Tango’s outlook?
The upside case requires vopimetostat to preserve activity and tolerability in larger cohorts, gain a practical regulatory path, scale manufacturing, establish biomarker testing, and compete against other PRMT5 and pathway agents. The June financing buys time, but it does not reduce biological uncertainty.
Which opportunities are most consequential?
What are the most material constraints?
- Clinical risk: early response rates may fall with more patients, longer follow-up, randomized controls, or broader sites.
- Regulatory risk: the FDA may require different endpoints, comparators, safety follow-up, or additional studies.
- Manufacturing concentration: Tango disclosed two CDMOs and only one drug-substance manufacturer, making supply continuity important.
- Competitive compression: better safety, efficacy, dosing, or trial execution from rival PRMT5 or MAT2A programs could reduce differentiation.
- Partner dependency: combination strategies rely on access to externally owned RAS, CDK4/6, and immunotherapy agents.
- Commercialization risk: Tango must build or buy launch capabilities, diagnostic pathways, market access, and post-approval supply.
- Dilution: the October 2025, Q1 2026, and June 2026 financings substantially expanded the potential share base.
Why does Tango Therapeutics matter for valuation?
A DCF based on current revenue is not useful because FY2025 collaboration revenue reflected deferred-revenue recognition and Q1 2026 revenue was zero. A better framework is risk-adjusted net present value by program and indication, using eligible patients, price, duration, market share, launch timing, margins, patent life, and probability of technical and regulatory success.
| Valuation driver | Tango-specific evidence | What would improve value | What would reduce value |
|---|---|---|---|
| Probability of success | Early combination ORR of 92% in 12 evaluable PDAC patients | Reproducible randomized efficacy and manageable safety | Regression toward weaker response or shorter durability |
| Addressable population | MTAP-deleted, RAS-mutant pancreatic and lung cancers plus other MTAP-deleted histologies | Validated biomarker prevalence and expansion into earlier lines | Narrow labeling, testing friction, or competing standards |
| Time to market | Phase 3 design planned for 2H 2026 | Regulatory agreement and efficient enrollment | Additional dose-finding, manufacturing, or confirmatory requirements |
| Commercial margin | No approved product or commercial cost base yet | Premium oncology pricing, durable treatment, scalable small-molecule manufacturing | High gross-to-net deductions, combination economics, or launch expense |
| Net cash and dilution | $379.8M at March 31, 2026 plus estimated $566.5M June net proceeds | Long runway through major readouts | Rapid burn, additional financing, option exercise, and equity compensation |
| Terminal exclusivity | PRMT5 patent families with expected expirations extending into 2041-2045 | Strong issued claims and regulatory exclusivity | Patent challenge, design-around, or lengthy development consuming exclusivity |
Which KPIs should a researcher monitor next?
Key KPIs are evaluable-patient count, confirmed response rate, six- and twelve-month progression-free survival, median PFS, response duration, Grade 3-plus treatment-related events, dose reductions, discontinuations, enrollment pace, pivotal-trial design, operating cash burn, vopimetostat spending, and fully diluted shares.
What is the key takeaway from Tango Therapeutics analysis?
Tango has shifted from a broad discovery-platform story to a late-development oncology story centered on vopimetostat. June 2026 combination data created a plausible route toward a targeted, chemotherapy-free pancreatic-cancer regimen, while the financing funded Phase 3 planning and commercialization preparation. TNG456, TNG260, TNG961, and partnered programs provide additional optionality.
The evidence remains early and non-randomized. A 92% response rate in 12 evaluable patients cannot establish durability, comparative benefit, regulatory acceptability, or commercial value. The decisive test is the move from dose-escalation data to a regulator-aligned randomized pivotal program.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.